Tags

Type your tag names separated by a space and hit enter

Evaluating Disease Severity in Chronic Pain Patients with and without Fibromyalgia: A Comparison of the Symptom Impact Questionnaire and the Polysymptomatic Distress Scale.
J Rheumatol. 2015 Dec; 42(12):2404-11.JR

Abstract

OBJECTIVE

To compare the relative effectiveness of the Polysymptomatic Distress Scale (PSD) with the Symptom Impact Questionnaire (SIQR), the disease-neutral revision of the updated Fibromyalgia Impact Questionnaire (FIQR), in their ability to assess disease activity in patients with rheumatic disorders both with and without fibromyalgia (FM).

METHODS

The study included 321 patients from 8 clinical practices with some 16 different chronic pain disorders. Disease severity was assessed by the Medical Outcomes Study Short Form-36 (SF-36). Univariate analyses were used to assess the magnitude of PSD and SIQR correlations with SF-36 subscales. Hierarchical stepwise regression was used to evaluate the unique contribution of the PSD and SIQR to the SF-36. Random forest regression probed the relative importance of the SIQR and PSD components as predictors of SF-36.

RESULTS

The correlations with the SF-36 subscales were significantly higher for the SIQR (0.48 to 0.78) than the PSD (0.29 to 0.56; p < 0.001). Stepwise regression revealed that the SIQR was contributing additional unique variance on SF-36 subscales, which was not the case for the PSD. Random forest regression showed SIQR Function, Symptoms, and Global Impact subscales were more important predictors of SF-36 than the PSD. The single SIQR pain item contributed 55% of SF-36 pain variance compared to 23% with the 19-point WPI (the Widespread Pain Index component of PSD).

CONCLUSION

The SIQR, the disease-neutral revision of the updated FIQ, has several important advantages over the PSD in the evaluation of disease severity in chronic pain disorders.

Authors+Show Affiliations

From the State University of New York (SUNY) at Stony Brook, Stony Brook, New York; Oregon Health and Science University, Portland, Oregon, USA.R. Friend, PhD, Professor of Psychology, Stony Brook University, and Adjunct Professor of Nursing, Oregon Health and Science University; R.M. Bennett, MD, Professor of Medicine and Nursing, Oregon Health and Science University. ronald.friend@stonybrook.edu.From the State University of New York (SUNY) at Stony Brook, Stony Brook, New York; Oregon Health and Science University, Portland, Oregon, USA.R. Friend, PhD, Professor of Psychology, Stony Brook University, and Adjunct Professor of Nursing, Oregon Health and Science University; R.M. Bennett, MD, Professor of Medicine and Nursing, Oregon Health and Science University.

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26523027

Citation

Friend, Ronald, and Robert M. Bennett. "Evaluating Disease Severity in Chronic Pain Patients With and Without Fibromyalgia: a Comparison of the Symptom Impact Questionnaire and the Polysymptomatic Distress Scale." The Journal of Rheumatology, vol. 42, no. 12, 2015, pp. 2404-11.
Friend R, Bennett RM. Evaluating Disease Severity in Chronic Pain Patients with and without Fibromyalgia: A Comparison of the Symptom Impact Questionnaire and the Polysymptomatic Distress Scale. J Rheumatol. 2015;42(12):2404-11.
Friend, R., & Bennett, R. M. (2015). Evaluating Disease Severity in Chronic Pain Patients with and without Fibromyalgia: A Comparison of the Symptom Impact Questionnaire and the Polysymptomatic Distress Scale. The Journal of Rheumatology, 42(12), 2404-11. https://doi.org/10.3899/jrheum.150443
Friend R, Bennett RM. Evaluating Disease Severity in Chronic Pain Patients With and Without Fibromyalgia: a Comparison of the Symptom Impact Questionnaire and the Polysymptomatic Distress Scale. J Rheumatol. 2015;42(12):2404-11. PubMed PMID: 26523027.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluating Disease Severity in Chronic Pain Patients with and without Fibromyalgia: A Comparison of the Symptom Impact Questionnaire and the Polysymptomatic Distress Scale. AU - Friend,Ronald, AU - Bennett,Robert M, Y1 - 2015/11/01/ PY - 2015/08/06/accepted PY - 2015/11/3/entrez PY - 2015/11/3/pubmed PY - 2016/9/15/medline KW - FIBROMYALGIA KW - FIBROMYALGIA IMPACT QUESTIONNAIRE KW - MEDICAL OUTCOMES STUDY SHORT FORM-36 KW - POLYSYMPTOMATIC DISTRESS KW - POLYSYMPTOMATIC DISTRESS SCALE KW - SYMPTOM IMPACT QUESTIONNAIRE SP - 2404 EP - 11 JF - The Journal of rheumatology JO - J. Rheumatol. VL - 42 IS - 12 N2 - OBJECTIVE: To compare the relative effectiveness of the Polysymptomatic Distress Scale (PSD) with the Symptom Impact Questionnaire (SIQR), the disease-neutral revision of the updated Fibromyalgia Impact Questionnaire (FIQR), in their ability to assess disease activity in patients with rheumatic disorders both with and without fibromyalgia (FM). METHODS: The study included 321 patients from 8 clinical practices with some 16 different chronic pain disorders. Disease severity was assessed by the Medical Outcomes Study Short Form-36 (SF-36). Univariate analyses were used to assess the magnitude of PSD and SIQR correlations with SF-36 subscales. Hierarchical stepwise regression was used to evaluate the unique contribution of the PSD and SIQR to the SF-36. Random forest regression probed the relative importance of the SIQR and PSD components as predictors of SF-36. RESULTS: The correlations with the SF-36 subscales were significantly higher for the SIQR (0.48 to 0.78) than the PSD (0.29 to 0.56; p < 0.001). Stepwise regression revealed that the SIQR was contributing additional unique variance on SF-36 subscales, which was not the case for the PSD. Random forest regression showed SIQR Function, Symptoms, and Global Impact subscales were more important predictors of SF-36 than the PSD. The single SIQR pain item contributed 55% of SF-36 pain variance compared to 23% with the 19-point WPI (the Widespread Pain Index component of PSD). CONCLUSION: The SIQR, the disease-neutral revision of the updated FIQ, has several important advantages over the PSD in the evaluation of disease severity in chronic pain disorders. SN - 0315-162X UR - https://www.unboundmedicine.com/medline/citation/26523027/Evaluating_Disease_Severity_in_Chronic_Pain_Patients_with_and_without_Fibromyalgia:_A_Comparison_of_the_Symptom_Impact_Questionnaire_and_the_Polysymptomatic_Distress_Scale_ L2 - http://www.jrheum.org/cgi/pmidlookup?view=long&amp;pmid=26523027 DB - PRIME DP - Unbound Medicine ER -